NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VYGR

Voyager Therapeutics Inc

Jul 07 • 04:00PM ET

3.04

Dollar change -0.16
Percentage change -5.00	%

Healthcare • Biotechnology • USA • NASD

Peers: QURE CRSP NTLA SRPT BLUE BOLD EDIT SGMO ADVM PGEN

| Held by: VTI IWM VXF IWN IBB DFAT VTWO DFAS AVSC IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.46	Insider Own	18.69%	Shs Outstand	55.21M	Perf Week	2.70%
Market Cap	168.23M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	-0.74%	Shs Float	45.00M	Perf Month	-8.43%
Enterprise Value	-25.79M	PEG	-	EPS next Q	-0.53	Inst Own	62.86%	Short Float	8.71%	Perf Quarter	-2.25%
Income	-84.69M	P/S	2.51	EPS this Y	-74.92%	Inst Trans	0.19%	Short Ratio	6.95	Perf Half Y	-46.38%
Sales	66.96M	P/B	0.62	EPS next Y	14.33%	ROA	-20.59%	Short Interest	3.92M	Perf YTD	-46.38%
Book/sh	4.94	P/C	0.71	EPS next 5Y	-12.46%	ROE	-27.61%	52W High	9.55 -68.17%	Perf Year	-59.95%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	15.83% 1.48%	ROIC	-27.56%	52W Low	2.64 14.93%	Perf 3Y	-48.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	28.83% -5.18%	Gross Margin	93.21%	Volatility	6.71% 6.91%	Perf 5Y	-75.10%
Dividend TTM	-	EV/Sales	-0.39	EPS Y/Y TTM	-8479.41%	Oper. Margin	-152.03%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.10	Sales Y/Y TTM	-43.75%	Profit Margin	-126.49%	RSI (14)	45.56	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	6.10	EPS Q/Q	-167.94%	SMA20	-4.32%	Beta	0.90	Target Price	15.78
Payout	-	Debt/Eq	0.15	Sales Q/Q	-66.83%	SMA50	-5.95%	Rel Volume	0.73	Prev Close	3.20
Employees	172	LT Debt/Eq	0.13	Earnings	May 06 AMC	SMA200	-37.06%	Avg Volume	563.64K	Price	3.04
IPO	Nov 11, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.12% -53.45%	Trades		Volume	414,136	Change	-5.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Dec-02-24	Initiated	Citigroup	Buy	$12
Nov-29-24	Resumed	Wedbush	Outperform	$7 → $11
Oct-16-24	Initiated	Leerink Partners	Outperform	$15
Mar-26-24	Initiated	Guggenheim	Buy	$22
Mar-19-24	Initiated	H.C. Wainwright	Buy	$30
Mar-07-24	Initiated	Citigroup	Buy	$16
Jan-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$14
May-10-23	Initiated	Truist	Buy	$18
Mar-10-23	Initiated	Oppenheimer	Outperform	$14
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform	$6 → $9
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral	$18 → $6
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral	$6
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$15 → $10
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$10
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform	$28 → $17
Mar-19-20	Initiated	The Benchmark Company	Buy	$18

Show Previous Ratings

Jun-10-25 07:00AM	Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
Jun-01-25 06:05AM	Oppenheimer Predicts Up to ~550% Jump for These 2 Strong Buy Stocks (TipRanks)
May-15-25 07:00AM	Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication (GlobeNewswire)
May-06-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.88%
04:01PM	Voyager Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
04:30PM	Loading…
Apr-28-25 04:30PM	Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-21-25 04:33PM	Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Mar-31-25 07:00AM	Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025 (GlobeNewswire) -7.40%
Mar-20-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm (GlobeNewswire) -5.13%
Mar-12-25 12:02PM	Q4 2024 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:25PM	Voyager Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire)
Mar-04-25 07:00AM	Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast (GlobeNewswire)
02:11AM	New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimers approach (Pharma Voice)
07:00AM	Loading…
Mar-03-25 07:00AM	Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease (GlobeNewswire)
Feb-25-25 07:00AM	Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-12-25 08:01AM	Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now (Insider Monkey) +5.11%
Feb-11-25 07:00AM	Voyager Provides Update on SOD1 ALS Gene Therapy Program (GlobeNewswire) -20.96%
Feb-06-25 07:00AM	Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-25 12:00PM	What Makes Voyager Therapeutics (VYGR) a New Buy Stock (Zacks)
Dec-29-24 06:22AM	Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-03-24 09:55AM	Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High? (Zacks) -5.19%
Nov-30-24 06:55AM	Wedbush upgrades Voyager to Outperform on pipeline progress (TipRanks)
Nov-20-24 07:00AM	Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease (GlobeNewswire)
Nov-13-24 08:37AM	Q3 2024 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:18AM	Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Nov-12-24 05:20PM	Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:19PM	Voyager Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Reports Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
07:00AM	Loading…
Nov-06-24 07:00AM	Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences (GlobeNewswire) +9.47%
Nov-05-24 07:00AM	Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast (GlobeNewswire)
Oct-28-24 10:01AM	Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-07-24 05:16AM	Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength? (Zacks)
Sep-16-24 07:00AM	Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected (GlobeNewswire)
Sep-05-24 08:00AM	Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14 (GlobeNewswire)
Aug-29-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Aug-07-24 07:00AM	Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire) -14.04%
Aug-06-24 05:15PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Voyager Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results (GlobeNewswire)
Jul-30-24 07:00AM	Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast (GlobeNewswire)
Jul-23-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-09-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-24 04:01PM	Voyager Therapeutics to Present at Multiple Virtual Investor Conferences (GlobeNewswire)
07:00AM	Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer (GlobeNewswire)
May-16-24 07:00AM	Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease (GlobeNewswire)
May-14-24 08:16AM	Q1 2024 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
06:27AM	Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating (MT Newswires)
03:03AM	Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 08:56PM	VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Voyager Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results (GlobeNewswire)
May-08-24 06:00AM	Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting (GlobeNewswire)
May-06-24 07:00AM	Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast (GlobeNewswire)
Apr-22-24 04:30PM	Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting (GlobeNewswire)
Apr-16-24 07:00AM	Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment (GlobeNewswire)
Mar-30-24 03:00AM	Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs. (Barrons.com)
Mar-26-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.21%
Mar-13-24 07:00AM	Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer (GlobeNewswire)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 11:09AM	Q4 2023 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.25%
09:54AM	Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:41PM	Voyager Therapeutics Inc (VYGR) Announces Strong Year-End Financials with Significant Cash Position (GuruFocus.com)
04:32PM	Voyager Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results (GlobeNewswire)
Feb-26-24 07:00AM	Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment (GlobeNewswire) +5.62%
Feb-21-24 07:00AM	Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast (GlobeNewswire)
Feb-20-24 07:00AM	Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research (GlobeNewswire)
Feb-07-24 07:00AM	Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference (GlobeNewswire)
Jan-11-24 10:09PM	Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024 (InvestorPlace)
Jan-04-24 10:45PM	Voyager Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -18.36%
04:14PM	Voyager Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Jan-03-24 11:15AM	Voyager (VYGR) Gains on Gene Therapy Deal With Novartis (Zacks) +19.67%
07:00AM	Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 04:07PM	Novartis Sweetens Its Deal With Voyager, And VYGR Stock Flashes A Bullish Sign (Investor's Business Daily) +6.64%
01:51PM	Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments (Investopedia)
10:46AM	VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today (InvestorPlace)
07:36AM	UPDATE 2-Novartis signs gene therapy deal with Voyager for $100 mln upfront (Reuters)
07:14AM	Voyager Therapeutics shares jump after $1.2 billion deal with Novartis (Reuters)
07:14AM	Novartis signs gene therapy deal with Voyager for $100 mln upfront (Reuters)
07:09AM	Novartis deepens ties with Voyager via $100M gene therapy deal (BioPharma Dive)
07:00AM	Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies (GlobeNewswire)
Dec-17-23 12:03PM	7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar (InvestorPlace)
Dec-08-23 10:13AM	12 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Dec-07-23 06:10AM	Voyager Therapeutics selects lead development candidate for SOD1 ALS gene therapy programme (Pharmaceutical Business Review)
Dec-06-23 07:00AM	Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program (GlobeNewswire)
Nov-07-23 10:16AM	Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.08%
Nov-06-23 05:22PM	Voyager Therapeutics Inc (VYGR) Reports Q3 2023 Financial Results (GuruFocus.com)
04:17PM	Voyager Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
Oct-30-23 07:00AM	Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (GlobeNewswire)
Sep-25-23 07:00AM	Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference (GlobeNewswire)
Sep-07-23 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-23 07:00AM	Voyager Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-23 08:14AM	11 Most Undervalued Biotech Stocks to Buy According to Analysts (Insider Monkey)
Aug-08-23 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-23 08:00AM	Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer (GlobeNewswire)

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ferguson Toby	Chief Medical Officer	Apr 02 '25	Sale	3.43	10,086	34,595	157,914	Apr 04 04:10 PM
Sandrock Alfred	President and CEO	Apr 02 '25	Sale	3.43	10,885	37,336	430,931	Apr 04 04:08 PM
Sandrock Alfred	Officer	Apr 02 '25	Proposed Sale	3.43	10,885	37,369		Apr 02 04:19 PM
Ferguson Toby	Officer	Apr 02 '25	Proposed Sale	3.43	10,086	34,624		Apr 02 04:11 PM
Carter Todd Alfred	Chief Scientific Officer	Feb 20 '25	Sale	4.26	3,305	14,079	77,718	Feb 24 04:21 PM
Sandrock Alfred	President and CEO	Feb 20 '25	Sale	4.24	11,702	49,616	296,816	Feb 24 04:20 PM
Swartz Robin	COO & CBO	Feb 20 '25	Sale	4.25	3,894	16,550	98,397	Feb 24 04:19 PM
Sandrock Alfred	Officer	Feb 20 '25	Proposed Sale	4.24	11,702	49,666		Feb 20 04:32 PM
Carter Todd Alfred	Officer	Feb 20 '25	Proposed Sale	4.26	3,305	14,075		Feb 20 04:21 PM
Swartz Robin	Officer	Feb 20 '25	Proposed Sale	4.25	3,894	16,557		Feb 20 04:13 PM
Carter Todd Alfred	Chief Scientific Officer	Feb 11 '25	Sale	4.45	5,413	24,088	81,023	Feb 12 04:22 PM
Swartz Robin	COO & CBO	Feb 11 '25	Sale	4.45	6,950	30,928	102,291	Feb 12 04:21 PM
Sandrock Alfred	President & CEO	Feb 11 '25	Sale	4.45	16,644	74,066	308,518	Feb 12 04:20 PM
Fahey Sandell Jacquelyn	Chief Legal Officer	Feb 11 '25	Sale	4.45	4,358	19,393	81,643	Feb 12 04:19 PM
Fahey Sandell Jacquelyn	Officer	Feb 11 '25	Proposed Sale	4.45	4,358	19,412		Feb 11 03:44 PM
Carter Todd Alfred	Officer	Feb 11 '25	Proposed Sale	4.45	5,413	24,110		Feb 11 03:40 PM
Sandrock Alfred	Officer	Feb 11 '25	Proposed Sale	4.45	16,644	74,046		Feb 11 03:37 PM
Swartz Robin	Officer	Feb 11 '25	Proposed Sale	4.45	6,950	30,938		Feb 11 03:36 PM
Swartz Robin	COO & CBO	Jan 14 '25	Sale	5.09	3,087	15,713	109,241	Jan 15 04:18 PM
Carter Todd Alfred	Chief Scientific Officer	Jan 14 '25	Sale	5.13	1,191	6,110	86,436	Jan 15 04:17 PM
Swartz Robin	Officer	Jan 14 '25	Proposed Sale	5.09	3,087	15,721		Jan 14 03:17 PM
Carter Todd Alfred	Officer	Jan 14 '25	Proposed Sale	5.13	1,191	6,106		Jan 14 03:14 PM
Swartz Robin	COO&CBO	Dec 23 '24	Sale	5.65	6,500	36,725	112,328	Dec 26 04:29 PM
Swartz Robin	Officer	Dec 23 '24	Proposed Sale	5.65	6,500	36,747		Dec 23 11:31 AM
Fahey Sandell Jacquelyn	Chief Legal Officer	Oct 02 '24	Sale	5.82	5,999	34,914	86,001	Oct 03 04:43 PM
Fahey Sandell Jacquelyn	Officer	Oct 02 '24	Proposed Sale	5.82	5,999	34,920		Oct 02 04:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VYGR

Voyager Therapeutics Inc

Upgrade your FINVIZ experience